Literature DB >> 20650968

A comparative analysis of assisted reproductive technology cycles in Australia and New Zealand 2004-2007.

C M Farquhar1, Y A Wang, E A Sullivan.   

Abstract

BACKGROUND: There are different funding arrangements for fertility treatments between New Zealand (NZ) and Australia. In NZ, there are two options for patients accessing treatment: either meeting specified criteria for age, no smoking and BMI for publicly funding or funding their own treatment. This differs from Australia, which has no explicit eligibility criteria restricting access to fertility treatment. An analysis of assisted reproductive technology (ART) in Australia and NZ was undertaken to consider the impact of these different funding approaches.
METHODS: Data were extracted from the Australian and New Zealand Assisted Reproduction Database between 2004 and 2007. A total of 116 111 autologous fresh cycles were included.
RESULTS: In Australia, more cycles were in women aged 40 years or older compared with those in NZ (23.5 versus 16.0%, P < 0.01). Single embryo transfer was more common in NZ than that in Australia, in women < 35 years of age (75.1 versus 59.6%, P < 0.01). In women <35 years, the crude rates of clinical pregnancy (37.5 versus 31.2%, P < 0.01) and live delivery (31.6 versus 26%, P < 0.01) following fresh ART cycles were significantly higher in NZ than that in Australia. These differences in outcomes persisted in older age groups.
CONCLUSIONS: The purpose of the criteria used in NZ to access public funding for fertility treatments is to optimize pregnancy outcomes. This approach has resulted in a healthier population of women undergoing treatment and may explain the improved pregnancy outcomes seen in NZ couples who undergo fertility treatments.

Entities:  

Mesh:

Year:  2010        PMID: 20650968     DOI: 10.1093/humrep/deq187

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  3 in total

1.  Should there be a female age limit on public funding for assisted reproductive technology?

Authors:  Drew Carter; Amber M Watt; Annette Braunack-Mayer; Adam G Elshaug; John R Moss; Janet E Hiller
Journal:  J Bioeth Inq       Date:  2013-01-04       Impact factor: 1.352

Review 2.  N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials.

Authors:  Divyesh Thakker; Amit Raval; Isha Patel; Rama Walia
Journal:  Obstet Gynecol Int       Date:  2015-01-08

3.  Perinatal mortality following assisted reproductive technology treatment in Australia and New Zealand, a public health approach for international reporting of perinatal mortality.

Authors:  Elizabeth A Sullivan; Yueping A Wang; Robert J Norman; Georgina M Chambers; Abrar Ahmad Chughtai; Cynthia M Farquhar
Journal:  BMC Pregnancy Childbirth       Date:  2013-09-18       Impact factor: 3.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.